IMRX – immuneering corporation - class a (US:NASDAQ)
Stock Stats
News
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models [Yahoo! Finance]
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Mizuho from $20.00 to $8.00. They now have a "buy" rating on the stock.
Form DEFA14A Immuneering Corp
Form DEF 14A Immuneering Corp For: Apr 23
Form SC 13G/A Immuneering Corp Filed by: Cormorant Asset Management, LP
Form SC 13G/A Immuneering Corp Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A Immuneering Corp Filed by: BlackRock Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.